Your browser doesn't support javascript.
loading
Stratifying quality of life outcome in subthalamic stimulation for Parkinson's disease.
Gronostay, Alexandra; Jost, Stefanie Theresa; Silverdale, Monty; Rizos, Alexandra; Loehrer, Philipp Alexander; Evans, Julian; Sauerbier, Anna; Indi, Donya; Leta, Valentina; Reker, Paul; Fink, Gereon Rudolf; Ashkan, Keyoumars; Antonini, Angelo; Nimsky, Christopher; Visser-Vandewalle, Veerle; Martinez-Martin, Pablo; Ray Chaudhuri, K; Timmermann, Lars; Dafsari, Haidar S.
Afiliação
  • Gronostay A; Department of Neurology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Jost ST; Department of Neurology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Silverdale M; Department of Neurology and Neurosurgery, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, Greater Manchester, UK.
  • Rizos A; Parkinson Foundation International Centre of Excellence, King's College Hospital, London, UK.
  • Loehrer PA; Department of Neurology, Philipps-University Marburg, Marburg, Germany.
  • Evans J; Department of Neurology and Neurosurgery, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, Greater Manchester, UK.
  • Sauerbier A; Department of Neurology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Indi D; Parkinson Foundation International Centre of Excellence, King's College Hospital, London, UK.
  • Leta V; Department of Neurology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Reker P; Parkinson Foundation International Centre of Excellence, King's College Hospital, London, UK.
  • Fink GR; Department of Neurology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Ashkan K; Department of Neurology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Antonini A; Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, Jülich, Germany.
  • Nimsky C; Parkinson Foundation International Centre of Excellence, King's College Hospital, London, UK.
  • Visser-Vandewalle V; Parkinson and Movement Disorders Unit, Department of Neurosciences (DNS), Padova University, Padova, Italy.
  • Martinez-Martin P; Department of Neurosurgery, Philipps-University Marburg, Marburg, Germany.
  • Ray Chaudhuri K; Department of Stereotactic and Functional Neurosurgery, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Timmermann L; Center for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain.
  • Dafsari HS; Parkinson Foundation International Centre of Excellence, King's College Hospital, London, UK.
J Neurol Neurosurg Psychiatry ; 95(7): 630-638, 2024 Jun 17.
Article em En | MEDLINE | ID: mdl-38124227
ABSTRACT

BACKGROUND:

Subthalamic nucleus deep brain stimulation (STN-DBS) for Parkinson's disease (PD) improves quality of life (QoL), motor and non-motor symptoms (NMS). However, in previous studies, 43%-49% of patients did not experience clinically relevant postoperative QoL improvement. To inform individualised prediction of postoperative QoL improvement, we developed a stratification analysis of QoL outcomes based on preoperative non-motor total burden, severity of motor progression and motor response in levodopa challenge tests.

METHODS:

This was a prospective, open-label, multicentre, international study with a 6-month follow-up. A distribution-based threshold identified 'QoL responders' in the PDQuestionnaire-8 Summary Index (PDQ-8 SI). After baseline stratification based on the NMS Scale, Hoehn and Yahr Scale and levodopa response assessed with the Unified PD Rating Scale-III, we compared postoperative QoL response between these strata. To assess the clinical usefulness and statistical feasibility of stratifications, we compared cumulative distribution function curves, respectively PDQ-8 within-stratum variation.

RESULTS:

All main outcomes improved postoperatively. Based on the 8.1 points threshold for clinically meaningful PDQ-8 SI improvement, only 80/161 patients were classified as 'QoL responders'. The absolute risk reductions for QoL non-response among respective non-motor, motor progression and levodopa response strata were 23%, 8% and 3%, respectively. Only non-motor stratification reduced PDQ-8 within-stratum variation compared with the overall cohort.

CONCLUSIONS:

Non-motor stratification, but not motor progression or levodopa response stratification, is clinically useful and statistically feasible for personalised preoperative prediction of postoperative QoL outcome of STN-DBS for PD. Our findings highlight that non-motor assessments are necessary components of a case-based, holistic approach of DBS indication evaluations geared towards optimising postoperative QoL outcomes. TRIAL REGISTRATION NUMBER GermanClinicalTrialsRegister #6735.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Qualidade de Vida / Núcleo Subtalâmico / Estimulação Encefálica Profunda Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Qualidade de Vida / Núcleo Subtalâmico / Estimulação Encefálica Profunda Idioma: En Ano de publicação: 2024 Tipo de documento: Article